|Bid||50.57 x 800|
|Ask||50.58 x 1200|
|Day's range||50.42 - 51.52|
|52-week range||34.98 - 54.17|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||85.59|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
PacBio's (PACB) product development activities raise optimism about the stock.
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Boston Scientific's (NYSE:BSX) stock is up by 9.1% over the past three months. However, the company's financials look a...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Boston Scientific fair value estimate is US$41.38 Current...
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.
Here is how Boston Scientific (BSX) and Aravive (ARAV) have performed compared to their sector so far this year.